Tirz40

Description

Tirzepatide Peptide Overview

Tirzepatide is a novel dual agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor from a single peptide molecule. This dual-incretin design has made it one of the most studied metabolic peptides in recent research.

Dual Incretin Receptor Activation

By simultaneously engaging the GIP and GLP-1 receptors, tirzepatide is studied for producing incretin signaling that influences insulin secretion and glucose handling more broadly than single-receptor agonists in research models.

Glucose-Dependent Insulin Secretion

Tirzepatide is studied for promoting glucose-dependent insulin release, meaning its insulinotropic activity is tied to elevated glucose levels in experimental models of glucose regulation.

Appetite and Energy Expenditure

Research on tirzepatide examines its effects on central appetite pathways and energy balance, with the GIP component of interest for its distinct contribution to metabolic signaling.

Extended Duration of Action

Like other modern incretin peptides, tirzepatide incorporates a fatty-acid modification for albumin binding and a prolonged half-life, a focus of pharmacokinetic research.

Specifications

• CAS Number: 2023788-19-2
• Molecular Formula: C225H348N48O68
• Molar Mass: 4813.45 g/mol
• Class: Dual GIP / GLP-1 receptor agonist (peptide)
• Storage: Refrigerate after reconstitution.
• Form: Lyophilized powder in a sterile glass vial.
• Purity: Minimum 99%
• Quantity: 40mg per vial
• Color: White

Important Note: This product is intended solely for in vitro laboratory research by licensed professionals. It is not approved by the FDA for human or animal use and should not be misbranded, misused, or mislabeled as a drug, food, supplement, or cosmetic.

References:

1. Coskun T. et al. – LY3298176, a novel dual GIP and GLP-1 receptor agonist – Molecular Metabolism
2. Frías J.P. et al. – Tirzepatide versus semaglutide (SURPASS-2) – New England Journal of Medicine
3. Dual incretin receptor pharmacology of tirzepatide – Diabetes
4. Tirzepatide and energy balance – Cell Metabolism